Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00820222 · ClinicalTrials.gov registry record · Phase 3
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
NCT00820222 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 540 participants.
The verdict
NCT00820222, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
Study Summary
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
Interventions
- DRUG trastuzumab
- DRUG capecitabine
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2009-04-14 |
| Est. Completion | 2018-03-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00820222
The ClinicalTrials.gov registry entry for NCT00820222 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which trastuzumab is the first listed.
NCT00820222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00820222 about?
NCT00820222 is a clinical study titled "Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer". This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
What is the current status of trial NCT00820222?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2009-04-14. Estimated completion is 2018-03-22.
What interventions are being tested in trial NCT00820222?
The interventions under investigation include: trastuzumab (DRUG), capecitabine (DRUG), lapatinib (DRUG).
Who is sponsoring clinical trial NCT00820222?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.